Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes - Ferrannini, Ele; Baldi, Simona; Frascerra, Silvia; Astiarraga, Brenno; Heise, Tim; Bizzotto, Roberto; Mari, Andrea; Pieber, Thomas R.; Muscelli, Elza (Diabetes (New York, N.Y.), 2016)
Keywords: 3-Hydroxybutyric Acid - agonists; 3-Hydroxybutyric Acid - blood; 3-Hydroxybutyric Acid - metabolism; Algorithms; Benzhydryl Compounds - administration & dosage; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; C-Reactive Protein - analysis; Carbohydrate Metabolism - drug effects; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - urine; Energy Metabolism - drug effects; Glucagon - blood; Glucagon - metabolism; Glucagon-Like Peptide 1 - blood; Glucose; Glucose Intolerance - blood; Glucose Intolerance - drug therapy; Glucose Intolerance - metabolism; Glucose Intolerance - urine; Glucosides - administration & dosage; Glucosides - adverse effects; Glucosides - therapeutic use; Glycosuria - chemically induced; Homeostasis; Hormones; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - blood; Insulin - metabolism; Insulin Secretion; Lipid Metabolism - drug effects; Lipolysis - drug effects; Membrane Transport Modulators - administration & dosage; Membrane Transport Modulators - adverse effects; Membrane Transport Modulators - therapeutic use; Renal Elimination - drug effects; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors; Substrates; Time Factors